Research
Hormonal
Tirzepatide (TZP) reduces HbA1c levels by −2.1% compared to insulin lispro U100 added to basal insulin.
TZP may be a more effective treatment option for lowering HbA1c in patients with T2D compared to insulin lispro.
StrongSupportsmedium confidence
In SURPASS-6, TZP was more effective than insulin lispro U100 added to basal insulin in reducing HbA1c levels at the study end (−2.1% vs. −1.1%, respectively).
Why this rating
Based on data from the SURPASS program, which includes human studies.
Source
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco et al. · Endocrines · 2024
reviewCited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →